BRAF
Apr 25 2025
FORTE: A Phase 2 Master Protocol Assessing Plixorafenib for BRAF-Altered Cancers
Read more
BRAF
Apr 25 2025
Circulating tumor DNA analysis in patients with BRAF-mutated advanced unresectable solid tumors treated with plixorafenib (FORE8394/PLX8394) in Phase 1/2a study
Read more
BRAF
Oct 21 2024
Activity of BRAF Inhibitor Plixorafenib (FORE8394) in Advanced Ovarian Cancer Harboring BRAF V600E Mutation
Read more
BRAF
Oct 17 2024
Safety & Efficacy of BRAF Inhibitor Plixorafenib in Children & Adults with Recurrent, BRAF altered PCNSTs
Read more
BRAF
Apr 17 2024
Paradox-Breaker BRAF inhibitor plixorafenib (FORE8394) synergizes with MEKi in BRAF V600 and non- V600 alterations
Read more
BRAF
Apr 17 2024
Efficacy of BRAF Inhibitor Plixorafenib (FORE8394) in Recurrent PCNST
Read more
BRAF
Apr 17 2024
Safety & Efficacy of BRAF Inhibitor FORE8394 Patients w. Advanced Solid & CNS Tumors
Read more
BRAF
Apr 16 2024
Dose optimization of novel BRAF inhibitor FORE8394 based on PK and efficacy results
Read more
BRAF
Sep 13 2022
Efficacy of BRAF Inhibitor FORE8394 in BRAF V600+ Patients
Read more
BRAF
May 20 2021
AACR Virtual Annual Meeting I: Insights Gained from AACR Project GENIE
Read more